Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Chinyu Su(Pfizer (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital), John K. Marshall(McMaster University), Nervin Lawendy(Pfizer (United States)), William J. Sandborn(University of San Diego), Julián Panés(Hospital Clínic de Barcelona), Silvio Danese(IRCCS Ospedale San Raffaele), James O. Lindsay(Barts Health NHS Trust), Alessandro Armuzzi, Brian Bressler(University of British Columbia), Konstantinos Tsilkos(Pfizer (United States)), Amy Marren(Pfizer (United States)), Haiying Zhang(Liaoning University of Traditional Chinese Medicine), Eric S. Maller(Pfizer (United States)), Gary Chan(Khoo Teck Puat Hospital), Leonardo Salese(Johnson & Johnson (United States))
Cited by 85
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
|Nature Cell Biology|2015|2.7k